| Assessment Status | Rapid Review complete |
| HTA ID | 22013 |
| Drug | Caplacizumab |
| Brand | Cablivi® |
| Indication | Treatment of adults and adolescents aged 12 years and older weighing at least 40 kg experiencing an episode of acquired thrombotic thrombocytopenic purpura (aTTP), in conjunction with plasma exchange and immunosuppression. |
| Assessment Process | |
| Rapid review commissioned | 07/03/2022 |
| Rapid review completed | 31/03/2022 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of caplacizumab compared with the current standard of care. |
| Full HTA commissioned by the HSE | 29/04/2022 |
The company has not submitted a HTA dossier to the NCPE, therefore the cost effectiveness of the technology could not be proven.